Systematic review with meta‐analysis: the efficacy of levofloxacin triple therapy as the first‐ or second‐line treatments of Helicobacter pylori infection

Summary Background Levofloxacin triple therapy has been used for the first‐line and second‐line treatment of Helicobacter pylori infection for more than 10 years. Aims To systematically review the efficacy of levofloxacin triple therapy in the first‐ and second‐line treatment, and to assess the time...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2016-09, Vol.44 (5), p.427-437
Main Authors: Chen, P.‐Y., Wu, M.‐S., Chen, C.‐Y., Bair, M.‐J., Chou, C.‐K., Lin, J.‐T., Liou, J.‐M.
Format: Article
Language:English
Subjects:
Adult
Amoxicillin - administration & dosage
Anti-Bacterial Agents - administration & dosage
Clinical Trials as Topic - methods
Databases, Factual
Drug Resistance, Bacterial
Drug Therapy, Combination
Helicobacter Infections - diagnosis
Helicobacter Infections - drug therapy
Helicobacter pylori - drug effects
Helicobacter pylori - physiology
Humans
Levofloxacin - administration & dosage
Prospective Studies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Levofloxacin triple therapy has been used for the first‐line and second‐line treatment of Helicobacter pylori infection for more than 10 years. Aims To systematically review the efficacy of levofloxacin triple therapy in the first‐ and second‐line treatment, and to assess the time trend and factors that might affect its efficacy. Methods Prospective trials reporting the efficacy of levofloxacin triple therapy in either the first‐line or second‐line treatment of H. pylori infection in adults were searched from the PubMed and Cochrane database from January 2000 to September 2015. Meta‐analysis was performed to calculate the cumulative eradication rate and the efficacies in subgroups. Results Of the 322 articles identified, a total of 4574 patients from 41 trials, including 16 trials in the first‐line treatment and 25 trials in the second‐line treatment were eligible for analysis. The cumulative eradication rate was 77.3% (95% confidence intervals, CI: 74.7–79.6) and was 80.7% (95% CI 77.1–83.7) in the first‐line treatment and 74.5% (95% CI: 70.9–77.8) in the second‐line treatment. The efficacies of levofloxacin triple therapy before 2008, between 2009 and 2011, and after 2012 were 77.4%, 79.6% and 74.8% respectively. The eradication rate was higher when levofloxacin was given once daily (80.6%, 95% CI: 77.1–83.7) than twice daily (73.6%, 95% CI: 69.7–77.2). The efficacy was significantly higher in levofloxacin‐susceptible strains than resistant strains (81.1% vs. 36.3%, risk ratio 2.18, 95% CI: 1.6–3, P 
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.13712